A systematic review of clinical outcomes and radiotherapy-associated toxicity in multicatheter accelerated partial breast irradiation

Lv, Yang; He, Lin; Wang, Chao; Zhang, Lijiu; Zhang, Biyuan; Song, Yuhua

doi:10.1097/md.0000000000014407

Cited by 5 publications

(3 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Few systematic reviews and meta-analyses were conducted to compare the effectiveness of distinct PBI approaches with WBI for the treatment of patients with breast cancer [39][40][41][42] , showing that the balance between benefit and risk of PBI appears optimal for low-risk women 43,44 . Several phase 3 trials on external beam PBI versus WBI showed non inferior local control and comparable rates of distant metastases, breast cancer specific and overall survival in selected patients at low risk of recurrence [45][46][47] .…”

Section: Statement 4 Low Risk-features Suitable For Partial Breast Ir...mentioning

confidence: 99%

European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer

Meattini

Becherini

Boersma

et al. 2022

The Lancet Oncology

176

View full text Add to dashboard Cite

Section: Statement 4 Low Risk-features Suitable For Partial Breast Ir...mentioning

confidence: 99%

European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer

Meattini

Becherini

Boersma

et al. 2022

The Lancet Oncology

176

View full text Add to dashboard Cite

“…2 Acute injury occurs during or a few months after radiotherapy and is usually self-limiting, including haematoma, dermatitis, breast pain and implant infection. 3 Late injury is that persisting at six months or occurring over six months after radiotherapy, and usually worsens with time. 4 The most common LRTI symptoms after breast cancer are pain, oedema, fibrosis, and limited range of motion of the arm at the shoulder joint.…”

Section: Introductionmentioning

confidence: 99%

The effect of hyperbaric oxygen treatment on late radiation tissue injury after breast cancer: A case-series of 67 patients

Spruijt¹,

Berg²

2020

Diving Hyperb Med

View full text Add to dashboard Cite

Introduction: Late radiation tissue injury (LRTI) after breast cancer may benefit from hyperbaric oxygen treatment (HBOT). This study aimed to report the LRTI symptom scores up to 12 months after HBOT and identify risk factors for poor scores. Methods: A case-series of 67 patients who underwent a mean of 44 sessions of HBOT was analysed. LRTI symptoms were scored at four time points using the LENT-SOMA scale (Late Effects in Normal Tissues – Subjective, Objective, Management, and Analytic), a visual analog scale for pain, and the range of shoulder motion. Results: Between starting HBOT and 12 months after HBOT 57 patients (85%) reported at least one point improvement in their LENT-SOMA score. Median pain and fibrosis scores improved significantly between the start and end of HBOT (P < 0.001), and remained stable three and 12 months after HBOT. The median breast oedema score improved significantly 12 months after HBOT (P = 0.003). Median shoulder abduction increased significantly from 90 to 165 degrees (P = 0.001) and median shoulder anteflexion increased significantly from 115 to 150 degrees (P = 0.004). Various risk factors were identified for poor scores despite HBOT; the most common risk factor was a poor score at start of HBOT. Conclusions: In this case-series, patients who underwent HBOT for LRTI after breast cancer reported significant improvement in pain, fibrosis, oedema, and shoulder movement. The improvement persisted up to 12 months after HBOT. A poor score at the start of HBOT was predictive for a poor score 12 months after HBOT.

show abstract

“…Partial breast irradiation can be administrated through various techniques, including external beam RT, intra‐operative RT and brachytherapy [ 103 , 104 , 105 , 106 ]. Studies comparing the effectiveness of different APBI approaches with whole breast irradiation showed that low‐risk patients appear to be the optimal population for APBI treatment, considering the balance between benefit and risk [ 107 , 108 , 109 , 110 , 111 ]. More and long‐term results of several past and ongoing prospective randomized APBI trials are awaited.…”

Section: Early Breast Cancer: Local‐regional Treatmentmentioning

confidence: 99%

Breast cancer: an up‐to‐date review and future perspectives

Hong

2022

Cancer Communications

152

View full text Add to dashboard Cite

Breast cancer is the most common cancer worldwide. The occurrence of breast cancer is associated with many risk factors, including genetic and hereditary predisposition. Breast cancers are highly heterogeneous. Treatment strategies for breast cancer vary by molecular features, including activation of human epidermal growth factor receptor 2 (HER2), hormonal receptors (estrogen receptor [ER] and progesterone receptor [PR]), gene mutations (e.g., mutations of breast cancer 1/2 [BRCA1/2] and phosphatidylinositol‐4,5‐bisphosphate 3‐kinase catalytic subunit alpha [PIK3CA]) and markers of the immune microenvironment (e.g., tumor‐infiltrating lymphocyte [TIL] and programmed death‐ligand 1 [PD‐L1]). Early‐stage breast cancer is considered curable, for which local‐regional therapies (surgery and radiotherapy) are the cornerstone, with systemic therapy given before or after surgery when necessary. Preoperative or neoadjuvant therapy, including targeted drugs or immune checkpoint inhibitors, has become the standard of care for most early‐stage HER2‐positive and triple‐negative breast cancer, followed by risk‐adapted post‐surgical strategies. For ER‐positive early breast cancer, endocrine therapy for 5‐10 years is essential. Advanced breast cancer with distant metastases is currently considered incurable. Systemic therapies in this setting include endocrine therapy with targeted agents, such as CDK4/6 inhibitors and phosphoinositide 3‐kinase (PI3K) inhibitors for hormone receptor‐positive disease, anti‐HER2 targeted therapy for HER2‐positive disease, poly(ADP‐ribose) polymerase inhibitors for BRCA1/2 mutation carriers and immunotherapy currently for part of triple‐negative disease. Innovation technologies of precision medicine may guide individualized treatment escalation or de‐escalation in the future. In this review, we summarized the latest scientific information and discussed the future perspectives on breast cancer.

show abstract

A systematic review of clinical outcomes and radiotherapy-associated toxicity in multicatheter accelerated partial breast irradiation

Abstract: Supplemental Digital Content is available in the text

Cited by 5 publications

References 44 publications

European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer

European Society for Radiotherapy and Oncology Advisory Committee in Radiation Oncology Practice consensus recommendations on patient selection and dose and fractionation for external beam radiotherapy in early breast cancer

The effect of hyperbaric oxygen treatment on late radiation tissue injury after breast cancer: A case-series of 67 patients

Breast cancer: an up‐to‐date review and future perspectives

Contact Info

Product

Resources

About